NEW YORK, June 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Osteoporosis Therapeutics Industry
http://www.reportlinker.com/p080451/Global-Osteoporosis-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, and MAB (Denosumab). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 49 companies including many key and niche players such as Abbott Laboratories, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Servier SA, Unigene Laboratories, Inc., and Warner Chilcott plc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3Bisphosphonates I-4Hormone Replacement Therapy/Estrogen Replacement Therapy I-4Estrogens I-4Estrogens/Progesterones I-4Calcitonins I-4Selective Estrogen Receptor Modulators (SERMs) I-4Other Therapeutics I-5II. EXECUTIVE SUMMARY
1. OUTLOOK II-1
Generic Incursion Drubs Market Revenues Worldwide II-1
Novel Therapies to Recuperate Market Growth II-2
Denosumab Bodes Significant Market Opportunities II-2
2. MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE II-3Bisphosphonates II-3The leading Therapeutic Market - Only for Now II-3ERT Drugs II-3Ups and Downs in the ERT Market II-3SERMs (Selective Estrogen Receptor Modulators) II-3Market Overview II-3Calcitonins II-4Market Overview II-4Monoclonal Antibodies (Denosumab) II-4Market Overview II-4New Drugs/Drug Classes in Pipeline II-4End-Stage Therapies (Under Development) for OsteoporosisPrevention/Cure II-4SERMs II-5Eli Lilly Drops Clinical Study of Arzoxifene for Bone Loss II-6Pfizer Intends to Withdraw NDAs for Fablyn II-6Bisphosphonates II-6Zoledronic Acid II-6Pamidronate II-6Calcitonin II-7Emisphere's Oral Calcitonin Candidate Fails to ClearClinical Trials II-7Parathyroid Hormone (PTH) II-7Novartis Terminates Clinical Study of Oral Formulation ofPTH1-34 II-7Monoclonal Antibodies - Denosumab II-7Table 1: Comparison of Major Osteoporosis Drugs in ReducingRisk of Fracture II-8RANK Ligand II-8Combination Therapy II-9Others II-9Cathepsin K inhibitors II-9Merck Releases New Data for Odanacatib II-9
3. MARKET DYNAMICS II-10
Facts & Figures: The Osteoporosis Primacy II-10
Snapshots II-10
Table 2: Prevalence of Osteoporosis and Osteopenia in Major
Markets including US, Germany, Italy, France, UK, Spain and
Japan: 2003-2013 (In Millions) (includes corresponding
Graph/Chart) II-10
Osteoporosis Therapeutics: An Evolutionary Scan II-10
Currently Available Drugs for Osteoporosis Treatment II-11
"A Sketch of the Present Industry Scenario" II-11
Factors Influencing Demand II-12
Altering Competitive Landscape in Osteoporosis Market II-12
Table 3: Leading Drugs in the Global Osteoporosis
Therapeutics Market (2006-2009): Value Sales for Actonel,
Fosamax, Evista, Boniva, Forteo and Aclasta/Reclast in US$
Million (includes corresponding Graph/Chart) II-13
Table 4: Leading Osteoporosis Therapies and its Cost per Day II-14Market Trends and Issues II-14Poor Disease Detection - A Major Market Constraint II-14Reluctance to Undergo HRT to Increase Osteoporosis Burden II-14Patent Expiries to Impact Market Growth II-14Limitations Bog Down Current Therapies II-15Growth Opportunities Galore for New Drugs II-15Bisphosphonates to Lose Market Value II-15Poor Compliance Mars Use of Bisphosphonates II-16Side Effects of HRT Fuel Natural Alternatives Sales II-16Bone Formation Drugs Augur New Prospects II-16A Sneak Into Various Options in Antiresorptives, AnabolicTherapeutics II-17Estrogen Replacement Therapy: Will Dosing Make a Difference? II-18Is Prevention Always Better Than Cure? II-18Peptide-Based Osteoporosis Therapy Gaining Ground II-18Polymorphism- A Potent Diagnostic Marker II-18Bisphosphonates - The Other Side II-19Efficacy of Evista under the Scanner II-19
4. PRODUCT OVERVIEW II-20
The "Silent Thief" II-20
An Introduction to Bone Physiology II-20
How Osteoporosis Steps In II-20
Osteoporosis: Major Types II-21
Primary Osteoporosis II-21
Secondary Osteoporosis II-21
Osteoporosis - The Aftermath II-22
Prevention: The Only Better Way Out II-22
Osteoporosis Therapies: A Cursory Glance II-23
Non-drug Therapy II-23
Drug Therapy II-23
Major Osteoporosis Therapeutic Classes: A Brief Review II-23
Bisphosphonates II-23
Classification of Bisphosphonates II-24
Alendronate II-24 Etidronate II-24
Risedronate II-24
Calcitonins: A Relatively Safer Therapeutic II-24
What It Is II-24
What It Does II-25
Major Types II-25
Salmon Calcitonin II-25
SERM: A Breakthrough II-25
Raloxifene: Most Widely Approved SERM II-25
SERMs: The Positive Angle II-26
SERMs: The Negative Side II-26
Hormone Replacement Therapy/Estrogen Replacement Therapy: The
Longstanding Therapeutic II-26
ERT: The Positive Side II-26
The Negative Angle to ERT II-27
Tereparatide: The First Anabolic Agent II-27
Composition II-27
Forteo: A Leading Brand II-27
Major Osteoporosis Therapeutic Classes at a Glance II-27
Osteoporosis Therapeutics: A Peek into the Major Brands II-28
5. PRODUCT INTRODUCTIONS/APPROVALS II-30Pfizer Launches Bazedoxifene in Japan II-30Daiichi Files for Approval of Denosumab in Japan II-30Amgen Obtains FDA Approval for Prolia (denosumab) in TreatingPost-Menopausal Osteoporosis II-30Amgen Obtains EC Approval for Marketing Prolia® II-31Teva to Launch Generic Version of Evista II-31Eli Lilly Obtains FDA Approval for Expanded Indication of Forteo® II-31WANBURY Introduces a Calcium Brand, CDENSE, in India II-32Yissum Launches New Compound for Osteoporosis Treatment II-32Novartis Bags US Approval for Reclast II-32Wyeth Obtains EC Approval for Conbriza™ II-32Ono and Astellas Introduce Bonoteo in Japan II-33European Commission Grants Approval to Pfizer for FABLYN® Tablets II-33
6. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE BUILDER II-34
MDRNA Receives Tentative Approval for New Osteoporosis Drug II-34
Novartis Receives EU Approval for Aclasta II-34
Sun Pharmaceutical Industries Receives Approval for Fosamax (S) II-34
Dr Reddy's Obtains Approval for Production and Marketing of
Generic Fosamax II-34
Aurobindo Pharma Obtains Approval for Introducing Sodium
Tablets in the US II-34
Procter & Gamble Obtains Approval for Actonel II-35
Eli Lilly Obtains European Commission Approval for FORSTEO® II-35
Ranbaxy Collaborates with Virchow to Introduce Bonista
Teriparatide Injection II-35
Barr Pharmaceuticals Subsidiary Introduces Generic
Osteoporosis Drug II-35
Teva Pharmaceutical Industries Obtains Approval for Generic
Fosamax® Tablets II-35
P&G Receives FDA Approval for New Dosage of Actonel II-36
Takeda Introduces Benet® for Osteoporosis Treatment II-36
Labtec Obtains Approval to Market Hormone Replacement Patch in
Europe II-36
Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA II-36
Merck's New Dosage of FOSAMAX PLUS D Gains FDA Approval II-37
Japanese Pharma Majors Receive Approval for Generic
Osteoporosis Drug II-37
Roche and GlaxoSmithKline Introduce Bonviva II-37
GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA
Approval II-38
Nycomed's Preotact Recommended for Approval in Europe II-38
Procter & Gamble and Sanofi-Aventis' Actonel Approved for Male
Osteoporosis II-38
Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray II-38
Teva Receives Tentative FDA Approval for Risedronate Sodium
Tablets II-39
GlaxoSmithKline and Roche Receive Approval for Bonviva in
Switzerland II-39
Roche's Once-a-month Bisphosphonate Gets FDA Nod II-39
Actonel with Calcium® Obtains FDA Approval II-40
FDA Approves Unigene's Nasal Calcitonin II-40
7. MAJOR CLINICAL TRIALS/FINDINGS II-41Azelon Pharmaceuticals Completes Phase II trails for ComparingNasal Spray Formulation of Teriparatide with Forteo,Administered Subcutaneously II-41GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics II-41Radius Initiates Phase II Trials for BA058 II-42Novartis and Nordic Initiate Phase III Clinical Trial of OralSalmon Calcitonin II-42Medivir Initiates First Human Trials for MIV-701 II-42Osteologix Begins Phase II Trial of NB S101 II-42Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C™ II-43Acceleron Initiates Phase I Clinical Trial of ACE-011 II-43Positive Results from Reclast Clinical Trials II-44
8. RECENT INDUSTRY ACTIVITY II-45
Sanofi Amends Agreement with Warner Chilcott for Actonel® II-45
Oramed and Laser Detect Systems Ink Joint Venture Agreement II-45
Orchid Chemicals and Pharmaceuticals, and Alvogen Ink Agreement II-45
Abbott Takes Over Solvay Pharmaceuticals II-45
Novartis Obtains Clearance To Continue Clinical Trials on Oral
Calcitonin II-46
Merck Merges with Schering-Plough II-46
Warner Chilcott Acquires Pharmaceuticals Business of P&G II-46
Unigene Laboratories Signs Agreement with Tarsa Therapeutics II-46
Bone Medical Obtains Formal Response from FDA for Capsitonin's
IND II-47
US District Court Confirms Validity of Eli Lilly's Patent for
Evista® II-47
US District Court Confirms Validity of Unigene's Patent for
Fortical® II-47
Ajinomoto Announces Japan Rights for Risedronate Hydrate from P&G II-47
Amgen and GSK Join Forces to Market Denosumab II-48
Galapagos-Lily Collaboration Achieves Milestone in
Osteoporosis Treatment II-48
EffRx and Nycomed Sign Licensing Deal for EX101 II-48
Pfizer Takes Over Wyeth II-49
Pfizer Obtains Complete Response Letter from US FDA for
Lasofoxifene II-49
Wockhardt Signs Agreement with DSM Nutritional for Launch of
Bonistein in India II-49
9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-50MorphoSys and Galapagos Form Long-Term Development Alliance II-50Daiichi Sankyo Establishes Ireland-Based Subsidiary II-50Merck and Japan Tobacco Sign Global Licensing Agreement forJTT-305 II-50Zelos Therapeutics Signs Agreements for Registration Study ofZT-031 II-50NuVasive Takes Over Osteocal Biologics Business of OsirisTherapeutics II-51Eli Lilly and TransPharma Medical Sign Licensing andDevelopment Agreement II-51Bone Medical Joins Hands with Hyundai Pharm. for Marketing PTHin South Korea II-52Eli Lilly to Acquire Osteoporosis Drug Patch from TransPharmaMedical II-52Wyeth Obtains Approvable Letter from FDA for Bazedoxifene II-52Daiichi Sankyo Establishes Subsidiary in Turkey II-52Aegis Therapeutics and Zelos Therapeutics Sign Agreement forZT-031 II-52Teijin Pharma Obtains a License from Dong Wha Pharm for DW-1350 II-53IOF Signs Agreements with Chinese Organizations forOsteoporosis Treatment II-53DAIICHI SANKYO Takes Over EVISTA® from Eli Lilly II-53Daiichi Sankyo Acquires Developing and Marketing Rights forDenosumab in Japan II-53Schering-Plough Acquires Organon BioSciences II-54Faes Farma Signs Marketing Agreement with Roche andGlaxoSmithKline II-54Alethia and Emerillon Collaborate on Osteoporosis Therapies II-54Ipsen Enters into Co-marketing Agreement with MSD II-55Unigene Enters into Agreement with Novartis II-55Pharming Group Granted Subsidies to Develop Osteoporosis Drugs II-55Procter & Gamble Terminates Nasal Spray Collaboration withNastech Pharmaceutical II-56Pharming Group Acquires DNage II-56Amgen Acquires Abgenix II-56P&G Licenses Osteoporosis Nasal Spray Rights from Nastech II-56Eli Lilly to Close Basingstoke Plant II-57Galapagos Acquires Drug Discovery Platform of Discovery Partners II-57Duravest Acquires Bio-Magnetic Therapy II-57Galapagos Acquires ProStrakan's ProSkelia II-58Roche Inks a Marketing Agreement with Elder Pharma II-58Chugai and Taisho Sign a Joint Development and MarketingAgreement II-58Theragenex Signs a Licensing Agreement with Zylera II-59Radius Acquires Licensing Agreement for Eisai's SERMs II-59Alkermes Partners with Eli Lilly to Develop and Market PTHFormulation II-59Radius Acquires Exclusive Rights to Karo Bio's SARMS II-59Unigene Enters into Agreement with Tzamal Bio II-60Galapagos Acquires Inpharmatica II-60Bio-Rad Acquires Provalis Medical Diagnostics Operations II-60Daiichi Sankyo to Market Evista in Europe II-60Biocon Acquires Nobex II-61Radius and Ipsen Enters into Licensing Agreement II-61Novartis Acquires Hexal AG II-61Nippon Chemiphar Signs Agreement with Velcura Therapeutics II-62Biopotential Capital Acquires Osta Biopharma II-62Dnage Commences DNA Research Programme for OsteoporosisTherapeutics II-62Nastech Initiates Phase I Study of PTH 1-34 II-62
10. FOCUS ON SELECT GLOBAL PLAYERS II-63
Eli Lilly and Company (US) II-63
F.Hoffmann-La Roche Ltd (Switzerland) II-63
Merck & Co., Inc. (US) II-63
Novartis AG (Switzerland) II-63
Pfizer, Inc. (US) II-63
Wyeth (US) II-64
Sanofi SA (France) II-64
Servier SA (France) II-65
Unigene Laboratories, Inc. (US) II-65
Warner Chilcott plc (Ireland) II-65
11. GLOBAL MARKET PERSPECTIVE II-66Table 5: World Recent Past, Current & Future Analysis forOsteoporosis Therapeutics by Geographic Region - US, Japan,Europe, and Rest of World Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2009 through2017 (includes corresponding Graph/Chart) II-66
Table 6: World Historic Review for Osteoporosis Therapeutics
by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-67
Table 7: World 15-Year Perspective for OsteoporosisTherapeutics by Geographic Region - Percentage Breakdown ofDollar Sales for US, Japan, Europe, and Rest of World Marketsfor Years 2003, 2011 & 2017 (includes correspondingGraph/Chart) II-68
Table 8: World Recent Past, Current & Future Analysis for
Bisphosphonates by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-69
Table 9: World Historic Review for Bisphosphonates byGeographic Region - US, Japan, Europe, and Rest of WorldMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2003 through 2008 (includescorresponding Graph/Chart) II-70
Table 10: World 15-Year Perspective for Bisphosphonates by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, and Rest of World Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) II-71
Table 11: World Recent Past, Current & Future Analysis for ERTDrugs by Geographic Region - US, Japan, Europe, and Rest ofWorld Markets Independently Analyzed with Annual Sales Figuresin US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) II-72
Table 12: World Historic Review for ERT (Estrogen Replacement
Therapy) Drugs by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-73
Table 13: World 15-Year Perspective for ERT (EstrogenReplacement Therapy)Drugs by Geographic Region - PercentageBreakdown of Dollar Sales for US, Japan, Europe, and Rest ofWorld Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) II-74
Table 14: World Recent Past, Current & Future Analysis for
SERMs by Geographic Region - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-75
Table 15: World Historic Review for SERMs (Selective EstrogenReceptors Modulators) by Geographic Region - US, Japan,Europe, and Rest of World Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) II-76
Table 16: World 15-Year Perspective for SERMs (Selective
Estrogen Receptors Modulators) by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Japan, Europe,
and Rest of World Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) II-77
Table 17: World Recent Past, Current & Future Analysis forCalcitonins by Geographic Region - US, Japan, Europe, and Restof World Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) II-78
Table 18: World Historic Review for Calcitonins by Geographic
Region - US, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-79
Table 19: World 15-Year Perspective for Calcitonins byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Japan, Europe, and Rest of World Markets for Years 2003,2011 & 2017 (includes corresponding Graph/Chart) II-80
Table 20: World Recent Past, Current & Future Analysis for MAB
(Denosumab) by Geographic Region - US, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-81
Table 21: World 15-Year Perspective for MAB (Denosumab) byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Japan, Europe, and Rest of World Markets for Years 2003,2011 & 2017 (includes corresponding Graph/Chart) II-82III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Industry Overview III-1
Osteoporosis in the US: An Insight III-1
Osteoporosis - An Underserved Market? III-1
Statistical Review III-1
Table 22: Osteoporosis Prevalence in Post-Menopause Women
(includes corresponding Graph/Chart) III-2
Table 23: Number of Osteoporosis Patients UndergoingOsteoporosis Therapies (In Thousands) (includescorresponding Graph/Chart) III-3Osteoporosis Prescription Market III-4Table 24: US Osteoporosis Prescription Market (2004-2006):Percentage Share of Leading Drugs - Fosamax, Actonel,Evista, Boniva, Forteo and Others (includes correspondingGraph/Chart) III-4Competitive Scenario III-4Table 25: Leading Players in the US Osteoporosis Market(2004 - A Historic Review) - Market Share by Value Salesfor Merck, Eli Lilly, Procter & Gamble/ Sanofi, and Others(includes corresponding Graph/Chart) III-5Competitive Review by Segment - A Historic Review III-5Bisphosphonates III-5Table 26: Leading Players in the US Bisphosphonates Market(2004) - Market Share by Value Sales for Merck and Procter& Gamble/ Sanofi (includes corresponding Graph/Chart) III-5SERMs III-6Calcitonins III-6Patent Expiry of Major Osteoporosis Drugs III-6B.Market Analytics III-7Table 27: The US Recent Past, Current & Future MarketAnalysis for Osteoporosis Therapeutics by Product Group -Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB(Denosumab) and Others Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2009 through2017 (includes corresponding Graph/Chart) III-7
Table 28: The US Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, Calcitonins and Others Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-8
Table 29: The US 15-Year Perspective for OsteoporosisTherapeutics by Product Group - Percentage Breakdown ofDollar Sales for Bisphosphonates, ERT Drugs, SERMs,Calcitonins, MAB (Denosumab) and Others Markets for Years2003, 2011 & 2017 (includes corresponding Graph/Chart) III-9
2. JAPAN III-10
Market Analytics III-10
Table 30: Japanese Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB
(Denosumab)Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-10
Table 31: Japanese Historic Review for OsteoporosisTherapeutics by Product Group - Bisphosphonates, ERT Drugs,SERMs, and Calcitonins Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-11
Table 32: Japanese 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs,
Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-12
3. EUROPE III-13A.Market Analysis III-13Forteo: The First Anabolic Agent in Europe III-13European Regulatory Restricts HRT III-13Calcitonin Embraces New Label III-13Table 33: European Market for Osteoporosis Therapeutics(2005- A Historic Review): Market Share of Leading Players-Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter &Gamble, Schering, Solvay and Others (includes correspondingGraph/Chart) III-14B.Market Analytics III-15Table 34: European Recent Past, Current & Future MarketAnalysis for Osteoporosis Therapeutics by Geographic Region-France, Germany, The UK, Italy, Spain, and Rest of EuropeMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) III-15
Table 35: European Historic Review for Osteoporosis
Therapeutics by Geographic Region - France, Germany, The UK,
Italy, Spain, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-16
Table 36: European 15-Year Perspective for OsteoporosisTherapeutics by Geographic Regions - Percentage Breakdown ofDollar Sales for France, Germany, The UK, Italy, Spain, andRest of Europe Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-17
Table 37: European Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB
(Denosumab) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-18
Table 38: European Historic Review for OsteoporosisTherapeutics by Product Group - Bisphosphonates, ERT Drugs,SERMs, and Calcitonins Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-19
Table 39: European 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs,
Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-20
3a. FRANCE III-21Market Analytics III-21Table 40: French Recent Past, Current & Future MarketAnalysis for Osteoporosis Therapeutics by Product Groups -Bisphosphonates, ERT Drugs, SERMs, and Calcitonins MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-21
Table 41: French Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-22
Table 42: French 15-Year Perspective for OsteoporosisTherapeutics by Product Group - Percentage Breakdown ofDollar Sales for Bisphosphonates, ERT Drugs, SERMs, andCalcitonins Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-23
3b. GERMANY III-24
Market Analytics III-24
Table 43: German Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-24
Table 44: German Historic Review for OsteoporosisTherapeutics by Product Group - Bisphosphonates, ERT Drugs,SERMs, and Calcitonins Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-25
Table 45: German 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and
Calcitonins Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-26
3c. ITALY III-27Market Analytics III-27Table 46: Italian Recent Past, Current & Future MarketAnalysis for Osteoporosis Therapeutics by Product Groups -Bisphosphonates, ERT Drugs, SERMs, and Calcitonins MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-27
Table 47: Italian Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-28
Table 48: Italian 15-Year Perspective for OsteoporosisTherapeutics by Product Group - Percentage Breakdown ofDollar Sales for Bisphosphonates, ERT Drugs, SERMs, andCalcitonins Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-29
3d. THE UNITED KINGDOM III-30
A.Market Analysis III-30
Table 49: Osteoporosis Population in the UK: 2004-2009 III-30
B.Market Analytics III-31
Table 50: The UK Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-31
Table 51: The UK Historic Review for OsteoporosisTherapeutics by Product Group - Bisphosphonates, ERT Drugs,SERMs, and Calcitonins Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-32
Table 52: The UK 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and
Calcitonins Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-33
3e. SPAIN III-34Market Analytics III-34Table 53: Spanish Recent Past, Current & Future MarketAnalysis for Osteoporosis Therapeutics by Product Groups -Bisphosphonates, ERT Drugs, SERMs, and Calcitonins MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-34
Table 54: Spanish Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-35
Table 55: Spanish 15-Year Perspective for OsteoporosisTherapeutics by Product Group - Percentage Breakdown ofDollar Sales for Bisphosphonates, ERT Drugs, SERMs, andCalcitonins Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-36
3f. REST OF EUROPE III-37
A.Market Analysis III-37
Romania III-37
B.Market Analytics III-37
Table 56: Rest of Europe Recent Past, Current & Future
Analysis for Osteoporosis by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-37
Table 57: Rest of Europe Historic Review for OsteoporosisTherapeutics by Product Groups - Bisphosphonates, ERT Drugs,SERMs, and Calcitonins Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-38
Table 58: Rest of Europe 15-Year Perspective for
Osteoporosis Therapeutics by Product Group - Percentage
Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-39
4. REST OF WORLD III-40A.Market Analysis III-40Prevalence of Osteoporosis in Various Region - At a Glance III-40Korea III-40Table 59: Korean Osteoporosis Therapeutics Market byLeading Brands (2005 - A Historic Review): Percentage ShareBreakdown by Dollar Sales for Fosamax, Atonel, Alend,Maxmarvil, and Others (includes corresponding Graph/Chart) III-40China III-40B.Market Analytics III-41Table 60: Rest of World Recent Past, Current & FutureAnalysis for Osteoporosis Therapeutics by Product Groups -Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB(Denosumab) Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) III-41
Table 61: Rest of World Historic Review for Osteoporosis
Therapeutics by Product Groups - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-42
Table 62: Rest of World 15-Year Perspective for OsteoporosisTherapeutics by Product Group - Percentage Breakdown ofDollar Sales for Bisphosphonates, ERT Drugs, SERMs,Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011& 2017 (includes corresponding Graph/Chart) III-43IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 49 (including Divisions/Subsidiaries - 63)
------------------------------------------Region/Country Players------------------------------------------The United States 24Canada 4Japan 7Europe 21France 3Germany 3The United Kingdom 3Italy 2Spain 1Rest of Europe 9Asia-Pacific (Excluding Japan) 5Middle East 2------------------------------------------
To order this report:Therapy Industry: Global Osteoporosis Therapeutics IndustryMore
Market Research ReportCheck our
Industry Analysis and InsightsCONTACT
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article